UT-MD Anderson Cancer Center: Metastasis-Directed Radiation Therapy Plus Hormone Therapy Improves Progression-Free Survival For Men With Advanced Prostate Cancer
October 26, 2022
October 26, 2022
HOUSTON, Texas, Oct. 26 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
MD Anderson presents results from Phase II EXTEND trial at ASTRO 2022
* * *
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic pr . . .
* * *
MD Anderson presents results from Phase II EXTEND trial at ASTRO 2022
* * *
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic pr . . .